Cargando…
A new era has begun: Treatment of atopic dermatitis with biologics
The era of biologics for the treatment of moderate-to-severe atopic dermatitis (AD) began in 2017 with the approval of dupilumab, a monoclonal antibody that binds to the α-subunit of the interleukin IL-4 receptor. Until then, only conventional immunosuppressants were available for systemic treatment...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dustri-Verlag Dr. Karl Feistle
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439107/ https://www.ncbi.nlm.nih.gov/pubmed/34532635 http://dx.doi.org/10.5414/ALX02259E |